For Healthcare Professionals

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Life expectancy ≤ 2 months
  2. Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
  3. Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
  4. Impaired cardiac function or clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria apply


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Lymphoma, Non-Hodgkin

Age (in years)

18+

Phase

Phase 1/Phase 2

Participants needed

348

Est. Completion Date

Apr 18, 2027

Treatment type

Interventional


Sponsor

Celgene

ClinicalTrials.gov identifier

NCT03930953

Study number

CC-99282-NHL-001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.